Evidence map›Paper›PMID 41331255›Full record

ArticleNature communications2025

SARS-CoV-2 EndoU-ribonuclease regulates RNA recombination and impacts viral fitness.

Yiyang Zhou, Yani P Ahearn, Kumari G Lokugamage, Angelica L Morgan, R Elias Alvarado, Leah K Estes, William M Meyers, Alyssa M McLeland, Jordan T Murray, Joseph R Rouse and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Yiyang Zhou *Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0001-8956-3229
Yani P Ahearn *Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Kumari G LokugamageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Angelica L MorganDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
R Elias AlvaradoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Leah K EstesDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
William M MeyersDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Alyssa M McLelandDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Jordan T MurrayDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Joseph R RouseDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Meenakshi KarDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Mehul S SutharDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2686-8380
David H WalkerDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Bryan A JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-8999-1255
Andrew L RouthDepartment of Microbiology and Immunology, Scripps Research, La Jolla, CA, USA. arouth@scripps.edu.ORCID http://orcid.org/0000-0002-2874-5990
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. Vineet.D.Menachery@emory.edu.ORCID http://orcid.org/0000-0001-8803-7606

Funding

Virology CoreU19AI171413 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SARKO, CHRISTOPHER · 2022 to 2023
$75.0M
EMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1M
RNA Recombination in CoronavirusesR01AI168232 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI VINEET D MENACHERY, Andrew Laurence Routh · 2023 to 2026
$2.1M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
NIAID NIH HHS R01 AI153602NIAID NIH HHS R01 AI168232NIAID NIH HHS T32 AI007526NIAID NIH HHS U19 AI171413U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI153602U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI171413
6 · The paper itself

Abstract

Coronaviruses (CoVs) maintain large RNA genomes that frequently undergo mutations and recombination, contributing to their evolution and emergence. In this study, we find that SARS-CoV-2 has greater RNA recombination frequency than other human CoVs. In addition, CoV RNA recombination primarily occurs at uridine (U)-enriched RNA sequences. Therefore, we next evaluate the role of SARS-CoV-2 NSP15, a viral endonuclease that targets uridines (EndoU), in RNA recombination and virus infection. Using a catalytically inactivated EndoU mutant (NSP15

Indexed as

COVID-19EndoribonucleasesRecombination, GeneticRNA, ViralSARS-CoV-2Viral Nonstructural ProteinsAnimalsGenome, ViralHumansMiceMutationUridineVero CellsVirus ReplicationEndoribonucleasesRNA, ViralUridineViral Nonstructural Proteins

Identifiers

PMID41331255
PMCPMC12783608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.